Search research articles
Contact Us
Filters
Showing results (1-10 of 108) with videos related to
Page
of 11
Sort By:
Seminars in Hematology
|
October 27, 2007
Autologous stem cell transplantation in myelodysplastic syndromes
Theo de Witte, Stefan Suciu, Ronald Brand, et al.
Pediatric Blood & Cancer
|
December 17, 2005
Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG Study 58881
Nicolas Sirvent, Stefan Suciu, Yves Bertrand, et al.
Cancer Treatment Reviews
|
August 21, 2003
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
Keith Wheatley, Natalie Ives, Barry Hancock, et al.
Current Opinion in Oncology
|
December 15, 2010
Autoimmunity and treatment outcome in melanoma
Marna G Bouwhuis, Timo L M Ten Hagen, Stefan Suciu, et al.
British Journal of Haematology
|
December 2, 2016
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine)
Michael Lübbert, Gabriele Ihorst, Philipp N Sander, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
Natalie J Ives, Stefan Suciu, Alexander M M Eggermont, et al.
Melanoma Research
|
July 8, 2009
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients
Pierre Vereecken, Ahmad Awada, Stefan Suciu, et al.
American Journal of Hematology
|
January 4, 2024
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial
Frédéric Baron, Fabio Efficace, Laura Cannella, et al.
Annals of Hematology
|
September 28, 2015
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
Theo de Witte, Stefan Suciu, Liv Meert, et al.
Melanoma Research
|
February 13, 2018
Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies
Alessandro A Testori, Stefan Suciu, Alexander C J van Akkooi, et al.
Page
of 11
Search research articles
Search
Showing results (1-10 of 108) with videos related to
Sort By:
Page
of 11
Seminars in Hematology
|
October 27, 2007
Autologous stem cell transplantation in myelodysplastic syndromes
Theo de Witte, Stefan Suciu, Ronald Brand, et al.
Pediatric Blood & Cancer
|
December 17, 2005
Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG Study 58881
Nicolas Sirvent, Stefan Suciu, Yves Bertrand, et al.
Cancer Treatment Reviews
|
August 21, 2003
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
Keith Wheatley, Natalie Ives, Barry Hancock, et al.
Current Opinion in Oncology
|
December 15, 2010
Autoimmunity and treatment outcome in melanoma
Marna G Bouwhuis, Timo L M Ten Hagen, Stefan Suciu, et al.
British Journal of Haematology
|
December 2, 2016
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine)
Michael Lübbert, Gabriele Ihorst, Philipp N Sander, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
Natalie J Ives, Stefan Suciu, Alexander M M Eggermont, et al.
Melanoma Research
|
July 8, 2009
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients
Pierre Vereecken, Ahmad Awada, Stefan Suciu, et al.
American Journal of Hematology
|
January 4, 2024
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial
Frédéric Baron, Fabio Efficace, Laura Cannella, et al.
Annals of Hematology
|
September 28, 2015
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
Theo de Witte, Stefan Suciu, Liv Meert, et al.
Melanoma Research
|
February 13, 2018
Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies
Alessandro A Testori, Stefan Suciu, Alexander C J van Akkooi, et al.
Page
of 11